Next Article in Journal
Impact of the First Wave of COVID-19 on Pediatric Oncology and Hematology: A Report from the French Society of Pediatric Oncology
Next Article in Special Issue
Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer
Previous Article in Journal
Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma
Previous Article in Special Issue
p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction
 
 
Article
Peer-Review Record

Saponin-Rich Extracts and Their Acid Hydrolysates Differentially Target Colorectal Cancer Metabolism in the Frame of Precision Nutrition

Cancers 2020, 12(11), 3399; https://doi.org/10.3390/cancers12113399
by Marta Gómez de Cedrón 1,*, Joaquín Navarro del Hierro 2,3, Marina Reguero 1,4, Sonia Wagner 1,5,†, Adrián Bouzas 1,6,†, Adriana Quijada-Freire 1, Guillermo Reglero 2,3, Diana Martín 2,3 and Ana Ramírez de Molina 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2020, 12(11), 3399; https://doi.org/10.3390/cancers12113399
Submission received: 20 October 2020 / Revised: 13 November 2020 / Accepted: 14 November 2020 / Published: 17 November 2020
(This article belongs to the Special Issue Cancer Targets for Personalized Therapy)

Round 1

Reviewer 1 Report

This study explored the effects of saponins-rich extracts from fenugreek and quinoa, named as FE and QE, respectively, and their hydrolyzed sapogenin-extract, named HFE and HQE, respectively on the colorectal cancer (CRC) cell lines. By means of cell bioenergetics analysis, authors found FE and HFE are effective neither QE or HQE is.

The fenugreek saponins and sapogenin-rich extracts target the molecular pathways related to lipid metabolism in the two CRC cell lines studied in different ways. It was clarified: FE inhibits the expression of TYMS1 and TK1, and synergizes with the chemotherapy drug 5-FluoroUracil-5FU, while HFE inhibits the target of lipid metabolism, resulting in a decrease in intracellular lipid content. In general, this study is interesting and provides novel results with significant information especially in the field of Precision Nutrition. However, there are some concerns should be clarified.

  1. It demonstrates that FE and HFE reduce mitochondrial oxidative phosphorylation and aerobic glycolysis at the cellular level. Does this result affect the performance of Hypoxia-inducible factor-1α (HIF-1α) and glucose transporter 1 (GLUT1)? As we know, the hypoxia-inducible factor 1α (HIF-1α) plays a major role in the tumor's response to hypoxia, and contributes to the tumor aggressiveness, invasiveness, and resistance to radiotherapy and chemotherapy.
  2. Hypoxia-inducible factor-1α (HIF-1α) and glucose transporter 1 (GLUT1) play an important role in the energy metabolism. What their roles in CRC should be researched and discussed.
  3. What’s your expect of applying FE / HFE to animal model?

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

In this manuscript Gomez de Cedron et al. investigated the effects of saponin-rich extracts and their hydrolyzates from plants on colorectal cancer metabolism. They show that fenugreek extracts inhibit colorectal cancer cells viability, reduce both mitochondrial OXPHOS and glycolytic rates, and modulate lipid metabolism, which might have a potential to be used against colorectal cancer in the context of precision nutrition. The manuscript is clear and well-written, except for some minor English language mistakes.

Minor points:

  • The title of the manuscript is not specific and precise enough, I’d suggest it to be changed, in order to represent the data obtained clearly.
  • Line 19 – add “related” after (second) cancer.
  • Line 25 – delete “being”.
  • Lines 25 – 26 and throughout the manuscript – “mitochondrial oxidative respiration” should be changed to “mitochondrial oxidative phosphorylation” or “mitochondrial respiration”.
  • Line 69 – define “T2DM”, and in general, any abbreviation, when appearing for the first time.
  • Line 102 – “reviews” instead of “revisions”.
  • Line 123 – you cannot say “effects on inhibition”, delete “on inhibition”.
  • Line 140 – what do you mean by “former” saponins?
  • Line 143 – again, it is the “effect”, not the inhibition.
  • Figure 1 – you should correct the concentration unit in all the panels to mg/ml.
  • Line 147 – IC50 values are not of CRC lines, correct it.
  • Lines 167 – 168 – delete between the brackets, you don’t have to put methodology used in the subsection title.
  • Line 176 – delete “very”.
  • Line 204 – the same as for lines 167 – 8.
  • Line 208 – it is probably by mistake, correct “2 × IC50” into “1 × IC50”.
  • Lines 209 - 214 - this belongs to the Materials and methods section.
  • Line 218 – what is “d2”?
  • Lines 225 – 226 – the effects on SW620 cell line deserve more description.
  • Figure 4 – y axis title should be changed into “fold change”.
  • Lines 245 – 249 – seem to belong more to the Introduction than Results section.
  • Line 296 – add “the incidence of” after “The increase in”.
  • Line 300 – metabolic function, not dysfunction is altered.
  • Lines 428 – 429 – should be rephrased.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop